FDA Recalls Prostaglandin E1 Injection for Lack of Sterility Assurance
Northern VA Compounders PLLC is recalling Prostaglandin E1 Injection Solution due to lack of sterility assurance. The recall affects 108 vials distributed nationwide.
The agency’s classification
FDA (Drugs): Class II
Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 3/5 (High).
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: FDA Class II recall with no reported illnesses or hospitalizations. The hazard—lack of sterility assurance—is significant for injectable medications but remains theoretical. This meets the criterion for High severity: a risk-of-harm product where injury has not yet been reported.
Plain-English summary
Northern VA Compounders PLLC is recalling Prostaglandin E1 Injection Solution, 25 mcg/mL in 2.5 mL multiple-dose vials. The affected lot number is 11252022@12, with an expiration date of 1/9/2023. The product was compounded by Akina Pharmacy in Sterling, Virginia. A total of 108 vials are subject to recall.
The recall was issued due to the manufacturer's inability to assure that the product met required sterility standards.
The affected product was distributed nationwide in the United States. Patients who may have received injections from affected vials should contact their healthcare provider. Remaining vials from this lot should not be used.
The recalled product
- Product
- Prostaglandin (E1) Injection Solution, 25mcg/ml, 2.5 mL Multiple-Dose vials, Rx Only, Compounded by: Akina Pharmacy, 23475 Rock Haven Way Suite 105, Sterling, VA 20166.
- Manufacturer
- Northern VA Compounders PLLC
- Category
- Drug — Injectable / Compounded
- Hazard
- Affected units
- 108
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot#: 11252022@12
- Exp 1/9/2023
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 25 recalled by Northern VA Compounders PLLC under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 25 products in this recall →Related recalls
Same manufacturer · Northern VA Compounders PLLC
See all →- HighQuadMix Plus Injectable Medication Recalled for Lack of Sterility Assurance
FDA (Drugs) · 2023-01-18
- HighTriMix Injection Recalled Due to Sterility Assurance Failure
FDA (Drugs) · 2023-01-18
- HighTriMix Injectable Recalled for Lack of Sterility Assurance
FDA (Drugs) · 2023-01-18
- HighTriMix Plus 002 Injectable Medication Recalled for Sterility Concerns
FDA (Drugs) · 2023-01-18
- HighCompounded Injectable Medication Recalled Due to Lack of Sterility Assurance
FDA (Drugs) · 2023-01-18
Same hazard · lack of sterility
See all →- SevereK.C. Pharmaceuticals Recalls Dry Eye Relief Eye Drops for Sterility Concerns
FDA (Drugs) · 2026-10-14
- SevereK.C. Pharmaceuticals Recalls Multiple Brands of Eye Drops for Sterility Concerns
FDA (Drugs) · 2026-10-14
- SevereClear Eyes Redness Relief Eye Drops Recalled for Sterility Concerns
FDA (Drugs) · 2026-09-30
- SevereClear Eyes Redness Relief Eye Drops Recalled for Sterility Assurance Issues
FDA (Drugs) · 2026-09-30
- SevereGentle Eyes Lubricant Eye Drops Recalled for Sterility Concerns
FDA (Drugs) · 2026-09-30
Similar recalls
- HighProstaglandin E1 Injection Recalled Due to Sterility Assurance Concerns
FDA (Drugs) · 2022-11-09
- SevereFDA Recalls Prostaglandin Tri-Mix Injection Due to Sterility Concerns
FDA (Drugs) · 2019-04-24
- SevereProstaglandin Injection Recalled for Lack of Sterility Assurance
FDA (Drugs) · 2019-04-24
- SevereFDA Recalls Prostaglandin Tri-Mix Vials Due to Sterility Concerns
FDA (Drugs) · 2019-04-24
- HighInjectable Prostaglandin E1 Multiple Strengths Recalled for Sterility Concerns
FDA (Drugs) · 2023-02-01
- SeverePharm D Solutions Recalls Prostaglandin E1 Injectable Due to Sterility Concerns
FDA (Drugs) · 2018-11-07